Join Clinical Trials for Healthy Volunteers in Queensland

All Categories Healthy Participants » Australia » Queensland

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Interventions: Drug: ALS-002158; Drug: Placebo
Sponsors: Alios Biopharma Inc.; Alios Biopharma Inc.; Vertex Pharmaceuticals Incorporated
Recruiting - verified March 2012
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

Conditions: Healthy; Cystic Fibrosis
Interventions: Drug: AeroVanc; Drug: IV vancomycin hydrochloride
Sponsors: Savara Inc.; Savara Inc.; INC Research Limited
Completed - verified May 2012
ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Condition: Obesity
Interventions: Drug: ZGN-440; Drug: ZGN-440 sterile diluent
Sponsors: Zafgen, Inc.; Zafgen, Inc.
Recruiting - verified January 2012
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified January 2012
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Biological: Serogroup B meningococcal vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified January 2012
Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers

Condition: Obesity
Interventions: Drug: ZGN-433; Drug: Normal Saline
Sponsors: Zafgen, Inc.; Zafgen, Inc.
Completed - verified December 2011
Observational Research in Childhood Infectious Diseases Study

Conditions: Respiratory Tract Infections; Gastrointestinal Infections
Intervention:
Sponsors: Queensland Children's Medical Research Institute; Queensland Children's Medical Research Institute; Royal Brisbane and Women's Hospital
Recruiting - verified June 2011
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Conditions: Ulcerative Colitis; Crohn's Disease
Interventions: Drug: AMG 181; Other: Placebo for AMG 181
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers

Condition: Healthy
Interventions: Biological: CSL112; Biological: Placebo
Sponsors: CSL Limited; CSL Limited
Completed - verified March 2012
Ross River Virus (RRV) Vaccine Study

Condition: Prophylaxis of Ross River Virus Infection
Intervention: Biological: Ross River Virus Vaccine
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Active, not recruiting - verified October 2011
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years

Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years

Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Condition: Ulcerative Colitis
Intervention: Drug: Amg 181
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers

Conditions: Healthy; Non-smokers
Intervention: Biological: Blood stage parasite (BSP) inoculum
Sponsors: Medicines for Malaria Venture; Medicines for Malaria Venture; Queensland Institute of Medical Research; Q-Pharm Pty Limited; Trident Clinical Research Pty Ltd
Completed - verified June 2011
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Condition: Encephalitis
Interventions: Biological: IC51; Biological: IC51; Biological: IC51
Sponsors: Intercell AG; Intercell AG
Recruiting - verified January 2012
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Condition: Pandemic H1N1 Influenza
Interventions: Biological: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations); Biological: GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

Condition: Obesity
Intervention: Drug: ZGN-433
Sponsors: Zafgen, Inc.; Zafgen, Inc.
Completed - verified January 2012
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Conditions: Bacterial Infections; Staphylococcal Vaccines; Immunotherapy, Active; Staphylococcal Skin Infections; Staphylococcal Infections
Interventions: Biological: SA3Ag vaccine; Procedure: Blood draw; Procedure: Colonization swab samples; Biological: SA3Ag followed by Placebo; Procedure: Blood draw; Procedure: Colonization swab samples; Biological: Placebo; Procedure: Blood draw; Procedure: Colonization swab samples; Biological: SA3Ag with no booster in stage 2; Procedure: Blood draw; Procedure: Colonization swab samples; Procedure: Placebo with no booster in stage 2; Procedure: Blood draw; Procedure: Colonization swab samples
Sponsors: Pfizer; Pfizer
Completed - verified August 2011
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

Condition: Meningococcal Disease
Intervention: Biological: MenACWY conjugate vaccine plus routine infant vaccines
Sponsors: Novartis; Novartis Vaccines
Completed - verified March 2012
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Conditions: Encephalitis; Japanese Encephalitis
Interventions: Biological: Live attenuated Japanese encephalitis virus, then ChimeriVax diluent; Biological: ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified May 2012
GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

Condition: Contraception
Intervention: Drug: Levonorgestrel IUS (LCS, BAY86-5028)
Sponsors: Bayer; Bayer
Active, not recruiting - verified March 2012
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

Condition: Influenza
Interventions: Biological: CSL Limited Influenza Virus Vaccine; Biological: CSL Limited Influenza Virus Vaccine; Biological: CSL Limited Influenza Virus Vaccine
Sponsors: CSL Limited; CSL Limited
Completed - verified August 2011
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Condition: Meningitis, Meningococcal
Interventions: Biological: meningococcal B rLP2086 vaccine.; Biological: meningococcal B rLP2086 vaccine.; Biological: meningococcal B rLP2086 vaccine.; Other: normal saline (placebo)
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012
Osteonecrosis of the Hip and Bisphosphonate Treatment

Condition: Osteonecrosis
Interventions: Drug: Zoledronic Acid; Drug: Placebo
Sponsors: University of Sydney; University of Sydney; Novartis
Recruiting - verified February 2011
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants

Conditions: Respiratory Syncytial Virus (RSV); Parainfluenza Virus Type 3 (PIV3)
Interventions: Biological: MEDI-534; Biological: MEDI-534; Biological: MEDI-534; Biological: MEDI-534; Biological: MEDI-534; Biological: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Active, not recruiting - verified May 2012
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B

Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza

Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

Condition: Influenza
Interventions: Biological: CSL Limited Influenza Vaccine; Biological: Placebo
Sponsors: CSL Limited; CSL Limited
Completed - verified August 2011
A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

Conditions: Healthy Subjects; Anaemia
Interventions: Drug: GSK626616, placebo, midazolam; Drug: omeprazole, caffeine, flurbiprofen, rosiglitazone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2011
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Conditions: Meningococcal Infection; Haemophilus Infection
Interventions: Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine); Biological: Priorix™; Biological: Hiberix™; Biological: Meningitec™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Condition: Herpes Simplex
Interventions: Biological: GSK208141; Biological: HavrixTM (investigational formulation); Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
A Clinical Study in the Use of Orthotics in Treating Pain in the Front of the Knee

Condition: Patellofemoral Pain Syndrome
Interventions: Procedure: Foot Orthotics; Procedure: Physiotherapy
Sponsors: The University of Queensland; The University of Queensland; National Health and Medical Research Council, Australia
Active, not recruiting - verified September 2006
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: imatinib mesylate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010